SeaStar Medical granted Canadian patent with claims covering SCD technology

SeaStar Medical announces the issuance by the Canadian Intellectual Property Office of Canadian Patent No. 2814586. This new patent has broad claims covering the Company’s Selective Cytopheretic Device, SCD, technology. Its issuance expands SeaStar Medical’s international patent rights and complements existing U.S. patent rights. “A significant opportunity exists to improve treatment of dysregulated hyperinflammatory response that can cause multiorgan damage and even death. The SCD is an innovative and proven approach that selectively targets highly active inflammatory cells to quell the hyperinflammatory response resulting from a range of conditions, and potentially reverse organ injury,” said Eric Schlorff, CEO of SeaStar Medical.